Early Phone Follow-Up Addresses Brachytherapy Side Effects

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 11
Volume 10
Issue 11

SAN DIEGO--The Cancer Center at Carle Clinic, Urbana, Illinois, has developed a phone assessment program to reach out to prostate brachytherapy patients before their 1-month follow-up visit, Mary Collins, RN, MSN, OCN, clinical nurse specialist at the Cancer Center, said at the 26th Annual Conference of the Oncology Nursing Society (abstract 73).

SAN DIEGO--The Cancer Center at Carle Clinic, Urbana, Illinois, has developed a phone assessment program to reach out to prostate brachytherapy patients before their 1-month follow-up visit, Mary Collins, RN, MSN, OCN, clinical nurse specialist at the Cancer Center, said at the 26th Annual Conference of the Oncology Nursing Society (abstract 73).

Patients who choose prostate seed implants to treat prostate cancer often experience side effects 7 to 10 days following the implant, but patients’ return visits are generally 1 month after the seed implant, Ms. Collins said.

"I developed this tool to call the patient 2 weeks after the implant to assess the side effects," she said. "Then, in collaboration with the physicians here, we developed a set of standard orders."

The assessment form used during the calls includes specific items about urinary and rectal symptoms, activity, and an open-ended question that addresses other possible concerns a patient may have. The nurse can refer to the standard orders to manage side effects the patient is experiencing. The forms, Ms. Collins said, were reviewed by the urologists, radiation oncologists, and nursing staff for accuracy and content.

"Some common side effects are frequency and urgency of urination and burning," she noted. "Those are the main three. Some men will also complain of frequent loose stools."

Surprisingly, she said, "many of these men say they are having these problems, but they think they just have to live with them. With this early assessment, they can get started on some form of treatment. When they come in for the scheduled visit 2 weeks later, the doctor can then assess how they’re doing."

Currently, Ms. Collins is the only person doing the phone assessment, and she’s been doing it for about a year and a half. "But I’d recommend this to other nurses who work with seed-implant patients," she said. "You can offer them a lot of reassurance and education on the phone." 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content